FGL1 and hepatocellular carcinoma: The results indicated that cell death due to sorafenib treatment in high-FGL1 expressing HCC cells (HepG2, Huh7, and Hep3B) was 2–3 times higher than that in low-FGL1 cells (Figure 2C).